VENOSTENT
VenoStent is a clinical-stage tissue engineering company that’s developed tunable, bioabsorbable smart polymer wraps in order to fundamentally transform the 5 million vascular surgeries performed each year. The company's technology is made from a new class of shape-memory polymers that are primarily used as an external stent in coronary artery bypass surgery and do not require sutures, allowing doctors to reduce surgery time, infection risk, and wound resuming in hemodialysis patients while also reducing failure from vein occlusion.
VENOSTENT
Industry:
Advanced Materials Biotechnology Health Care Life Science Medical Device
Founded:
2017-01-01
Address:
Houston, Texas, United States
Country:
United States
Website Url:
http://www.venostent.com
Total Employee:
11+
Status:
Active
Total Funding:
29.82 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon Content Delivery Network LetsEncrypt Amazon SSL By Default HSTS Google Apps For Business
Similar Organizations
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Instadiagnostics
Instadiagnostics Inc., is developing a rapid, quantitative, point-of-care (POC) diagnostic platform.
nference
nference is an Artificial Intelligence (AI)-powered venture creation engine
Pera Labs
Pera Labs develops digiceuticals and AI-powered solutions for fertility.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Current Advisors List
Current Employees Featured
Founder
Investors List
Good Growth Capital
Good Growth Capital investment in Series A - VenoStent
National Institutes of Health
National Institutes of Health investment in Grant - VenoStent
Norwest Venture Partners
Norwest Venture Partners investment in Series A - VenoStent
IAG Capital Partners
IAG Capital Partners investment in Series A - VenoStent
Creative Ventures
Creative Ventures investment in Series A - VenoStent
SNR.vc
SNR.vc investment in Series A - VenoStent
TMC Venture Fund
TMC Venture Fund investment in Series A - VenoStent
IAG Capital Partners
IAG Capital Partners investment in Series A - VenoStent
Alumni Ventures
Alumni Ventures investment in Series A - VenoStent
Baylor Angel Network
Baylor Angel Network investment in Series A - VenoStent
Official Site Inspections
http://www.venostent.com Semrush global rank: 9.71 M Semrush visits lastest month: 327
- Host name: 76.76.21.21
- IP address: 76.76.21.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "VenoStent"
Bioengineered Vascular Support
Our cross-disciplinary team, with expertise in biomedical engineering, materials engineering and medical 3D printing, is applying this unique technology to improve the lives of vascular surgery …See details»
Company - VenoStent
We’re a clinical-stage therapeutic medical device company that’s developed finely-tuned, bioabsorbable wraps intended to improve outcomes for the 5 million vascular surgeries …See details»
VenoStent - Crunchbase Company Profile & Funding
VenoStent is a clinical-stage tissue engineering company that’s developed tunable, bioabsorbable smart polymer wraps in order to fundamentally transform the 5 million vascular surgeries performed each year.See details»
VenoStent, Inc. - LinkedIn
Developing bioresorbable smart polymer scaffolds to transform vascular surgery | VenoStent is a venture backed, clinical stage medical device and tissue engineering company developing ...See details»
Patients & Providers - VenoStent
The SAVE-FistulaS trial is a multi-center, prospective, randomized, double-arm, single-blind, evaluator-blinded clinical trial for chronic kidney disease (CKD) patients referred for creation of a new arteriovenous fistula (AVF).See details»
VenoStent Company Profile 2024: Valuation, Funding …
Developer of a biomedical engineering technology designed to improve the quality and length of life for dialysis patients.See details»
VenoStent, Inc. - VentureRadar
VenoStent is a therapeutic medical device company developing a bioabsorbable wrap, SelfWrap, to transform outcomes in vascular surgery, starting with hemodialysis access.See details»
Venostent, Inc. Company Profile | Houston, TX - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Venostent, Inc. of Houston, TX. Get the latest business insights from Dun & Bradstreet.See details»
VenoStent Company Profile - Office Locations, Competitors ... - Craft
VenoStent is a medical device and biomaterial platform. It develops SelfWrap, a perivascular wrap designed to reduce failures at the vein-artery or vein-graft junction of dialysis patients. The …See details»
VenoStent Company Profile: Overview and Full News Analysis
VenoStent is a Texas-based company specializing in bioengineered vascular support, particularly focusing on improving vascular surgery outcomes, starting with renal dialysis access. Their …See details»
VenoStent raises $16M series A - InnovationMap
Jul 31, 2023 · VenoStent, Inc., a company developing an innovative tool to improve outcomes for hemodialysis patients, has closed $16 million in a series A round of financing. Two Charleston, South Carolina-based firms — Good …See details»
VenoStent Completes $20 Million Series A with $4 Million …
Jun 27, 2024 · VenoStent, Inc., a clinical-stage medical device company developing a novel therapeutic device for improving dialysis patient outcomes, announced today that it closed an …See details»
VenoStent Accepted into Y Combinator and Closes …
Jun 24, 2020 · YC will help VenoStent establish more strategic partnerships, aid fundraising and business development efforts, and expand the platform potential of its materials. VenoStent …See details»
VenoStent Completes $20 Million Series A with $4 Million …
Jun 27, 2024 · VenoStent, Inc. (www.venostent.com) is a therapeutic medical device company developing a bioabsorbable wrap, SelfWrap, to transform outcomes in vascular surgery, …See details»
VenoStent has a new technology to improve outcomes for dialysis ...
Aug 9, 2020 · Timothy Boire and his co-founder Geoffrey Lucks were both near broke when they moved to Dallas to join the first accelerator they entered after forming VenoStent, a company …See details»
VenoStent, Inc. | VentureRadar
VenoStent is a therapeutic medical device company developing a bioabsorbable wrap, SelfWrap, to transform outcomes in vascular surgery, starting with hemodialysis access. The device is …See details»
Home - SAVE FistulaS Clinical Trial
At VenoStent, we are working to improve the usability and durability of AVFs for more reliable dialysis. This could have a positive impact on patient care and quality of life for chronic kidney …See details»
News & Press - VenoStent
Oct 26, 2021 · VenoStent Completes $16M Series A Financing, Receives IDE Approval from FDA to Begin US TrialSee details»
VenoStent: The Promise of Safer Treatment for Dialysis Patients
Jun 27, 2024 · VenoStent, an innovative medical device company based in Houston, Texas, is aiming to dramatically improve outcomes for AVF patients with its bioabsorbable perivascular …See details»
How SelfWrap Works - VenoStent
SelfWrap aims to reduce inward growth or occlusion/stenosis of AV access sites by providing biomimetic mechanical support, improving hemodynamics, and promoting outward vein …See details»